

Transdermal Drug Delivery Systems Market by Type of Delivery System [Passive (Matrix System and Reservoir System), Active [Structure Based, Electrical Based, (Iontophoresis, Electroporation, and Sonophoresis), and Others] and Application (Analgesics, Hormone Replacement Therapy, Cardiovascular Disorders, Motion Sickness, and Smoking Cessation) - Global Opportunity Analysis and Industry Forecast, 2017-2023

https://marketpublishers.com/r/T5E5EA394B6EN.html

Date: June 2017

Pages: 150

Price: US\$ 5,540.00 (Single User License)

ID: T5E5EA394B6EN

Abstracts

Transdermal route is a promising alternative for oral and injectable drug delivery wherein skin is the primary site for drug administration. This drug delivery system offers certain benefits, such as non-invasiveness, controlled & complete drug delivery from the dosage form and improved patient compliance. Transdermal patches, ointments, gel and implants are the popular transdermal drug delivery systems. Over the past few years, transdermal patches have gained significant importance. The transdermal drug delivery market has witnessed vertical growth over the past few decades and this trend is expected to continue during the forecast period. This growth would be driven by the steadily growing number of transdermal drug delivery products in the market resulting from the widespread adoption of these products by consumers. Johnson and Johnson, Acrux, Antares Pharma, Dermatrends Inc., Bayer HealthCare Pharmaceuticals, Novartis, Janssen Pharmaceuticals Inc. and Durect Corporation are some of the key leaders in the global transdermal drug delivery systems market. Recently, NuPathe Inc. received FDA clearance for their transdermal patch, Zeltrix. It is a single use preparation intended for the treatment of migraine pain.

The global transdermal drug delivery systems market is segmented on the basis of



application, technology and geography. The application segment is further categorized into CNS, Pain Management, Hormone, Cardiovascular and Others. Transdermal patches for pain management and hormonal drug delivery dominate the market. Vivelle-dot and Climara are estrogen patches currently available in the market, offered by Novartis and Bayer HealthCare Pharmaceuticals, respectively. They are used in the delivery of estradiol for hormone replacement therapy. Based on technology, the global transdermal drug delivery systems market is segmented into Electroporation, Electric current, Lontophoresis, Radio Frequency, Microporation, Thermal, Mechanical arrays and Ultrasound. These technologies form an efficacious drug delivery system by improving the drug distribution pattern across the skin. Geographically, the global transdermal drug delivery systems market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominate the global market due to extensive R&D efforts and presence of numerous approved transdermal products.

KEY BENEFITS

This report offers the following benefits in particular:

In-depth coverage of the global transdermal drug delivery systems market including drivers, restraints and opportunities would help professionals to better understand market behavior

Detailed study of the strategies of key leaders, partnerships and acquisitions in the global transdermal drug delivery systems market would be informative for professionals in the corporate sector

Porter's Five Forces analysis examines the competitive structure of the global transdermal drug delivery systems market and would assist market strategists in making decisions.

Pin-point analysis of geographic segments helps to identify opportunities for growth within the global transdermal drug delivery systems market

KEY MARKET SEGMENTS

The global transdermal drug delivery systems market is segmented into three major categories: application, technology and geography.



MARKET BY APPLICATION

	CNS
	Pain Management
	Hormone
	Cardiovascular
	Others
MARKET BY TECHNOLOGY	
	Electroporation
	Electric current
	Lontophoresis
	Radio Frequency
	Microporation
	Thermal
	Mechanical arrays
	Ultrasound
MARKET BY GEOGRAPHY	
	North America
	Europe
	Asia-Pacific



LAMEA



Contents

CHAPTER 1 INTRODUCTION

- 1.1. REPORT DESCRIPTION
- 1.1. KEY BENEFITS
- 1.2. KEY MARKET SEGMENTS
- 1.3. RESEARCH METHODOLOGY
 - 1.3.1. Secondary research
 - 1.3.2. Primary research
 - 1.3.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1. KEY FINDINGS OF THE STUDY
- 2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

- 3.1. MARKET DEFINITION AND SCOPE
- 3.2. KEY FINDINGS
 - 3.2.1. Top investment pockets
 - 3.2.2. Top winning strategies
 - 3.2.2.1. Competitive intelligence of companies and their strategies
- 3.3. MARKET SHARE ANALYSIS, 2016
- 3.4. MARKET DYNAMICS
 - 3.4.1. Drivers
 - 3.4.1.1. Rising geriatric population
 - 3.4.1.2. Increasing prevalence of chronic disorders
 - 3.4.1.3. Rise in adoption of third-generation delivery systems
 - 3.4.2. Restraints
 - 3.4.2.1. Side-effects of the systems
 - 3.4.3. Opportunities
 - 3.4.3.1. Emerging nations

CHAPTER 4 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM

4.1. OVERVIEW



- 4.1.1. Market size and forecast
- 4.2. PASSIVE DELIVERY SYSTEM
 - 4.2.1. Key market trends
 - 4.2.2. Growth factors and opportunities
 - 4.2.3. Market size and forecast
 - 4.2.3.1. Matrix delivery system
 - 4.2.3.1.1. Market size and forecast
 - 4.2.3.2. Reservoir delivery system
 - 4.2.3.2.1. Market size and forecast
- 4.3. ACTIVE DELIVERY SYSTEM
 - 4.3.1. Key market trends
- 4.3.2. Growth factors and opportunities
- 4.3.3. Market size and forecast
 - 4.3.3.1. Structure-based drug delivery system
 - 4.3.3.1.1. Market size and forecast
 - 4.3.3.2. Electrically-based drug delivery system
 - 4.3.3.2.1. Market size and forecast
 - 4.3.3.2.2. Iontophoresis
 - 4.3.3.2.2.1. Market size and forecast
 - 4.3.3.2.3. Electroporation
 - 4.3.3.2.3.1. Market size and forecast
 - 4.3.3.2.4. Sonophoresis
 - 4.3.3.2.4.1. Market size and forecast
 - 4.3.3.3. Other
 - 4.3.3.3.1. Market size and forecast

CHAPTER 5 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION

- 5.1. OVERVIEW
 - 5.1.1. Market size and forecast
- 5.2. ANALGESICS
 - 5.2.1. Market size and forecast
- 5.3. HORMONE REPLACEMENT THERAPY
 - 5.3.1. Market size and forecast
- 5.4. HYPERTENSION
 - 5.4.1. Market size and forecast
- 5.5. MOTION SICKNESS
- 5.5.1. Market size and forecast



5.6. SMOKING CESSATION

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION

- 6.1. OVERVIEW
 - 6.1.1. Market size and forecast
- 6.2. NORTH AMERICA
 - 6.2.1. Key market trends
 - 6.2.2. Growth factors and opportunities
 - 6.2.3. Market size and forecast
- 6.3. EUROPE
 - 6.3.1. Key market trends
 - 6.3.2. Growth factors and opportunities
 - 6.3.3. Market size and forecast
- 6.4. ASIA-PACIFIC
 - 6.4.1. Key market trends
 - 6.4.2. Growth factors and opportunities
 - 6.4.3. Market size and forecast
- 6.5. LAMEA
 - 6.5.1. Key market trends
 - 6.5.2. Growth factors and opportunities
 - 6.5.3. Market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ACRUX LIMITED

- 7.1.1. Company overview
- 7.1.2. Company snapshot
- 7.1.3. Operating business segments
- 7.1.4. Business performance
- 7.1.5. Key strategic moves and developments
- 7.1.6. Strategy share (%)

7.2. BAYER AG

- 7.2.1. Company overview
- 7.2.2. Company snapshot
- 7.2.3. Operating business segments



- 7.2.4. Business performance
- 7.2.5. Key strategic moves and developments
- 7.2.6. Strategy share (%)

7.3. BOEHRINGER INGELHEIM GMBH

- 7.3.1. Company overview
- 7.3.2. Company snapshot
- 7.3.3. Operating business segments
- 7.3.4. Business performance
- 7.3.5. Key strategic moves and developments
- 7.3.6. Strategy share (%)

7.4. BRISTOL-MYERS SQUIBB COMPANY

- 7.4.1. Company overview
- 7.4.2. Company snapshot
- 7.4.3. Operating business segments
- 7.4.4. Business performance
- 7.4.5. Key strategic moves and developments
- 7.4.6. Strategy share (%)

7.5. ECHO THERAPEUTICS, INC.

- 7.5.1. Company overview
- 7.5.2. Company snapshot
- 7.5.3. Operating business segments
- 7.5.4. Business performance
- 7.5.5. Key strategic moves and developments
- 7.5.6. Strategy share (%)

7.6. ENDO PHARMACEUTICALS INC.

- 7.6.1. Company overview
- 7.6.2. Company snapshot
- 7.6.3. Operating business segments
- 7.6.4. Business performance
- 7.6.5. Key strategic moves and developments
- 7.6.6. Strategy share (%)

7.7. GLAXOSMITHKLINE PLC

- 7.7.1. Company overview
- 7.7.2. Company snapshot
- 7.7.3. Operating business segments
- 7.7.4. Business performance
- 7.7.5. Key strategic moves and developments
- 7.7.6. Strategy share (%)

7.8. JOHNSON & JOHNSON



- 7.8.1. Company overview
- 7.8.2. Company snapshot
- 7.8.3. Operating business segments
- 7.8.4. Business performance
- 7.8.5. Key strategic moves and developments
- 7.8.6. Strategy share (%)
- 7.9. MYLAN N.V.
 - 7.9.1. Company overview
 - 7.9.2. Company snapshot
 - 7.9.3. Operating business segments
 - 7.9.4. Business performance
 - 7.9.5. Key strategic moves and developments
 - 7.9.6. Strategy share (%)
- 7.10. NOVARTIS AG
 - 7.10.1. Company overview
 - 7.10.2. Company snapshot
 - 7.10.3. Operating business segments
 - 7.10.4. Business performance
 - 7.10.5. Key strategic moves and developments
 - 7.10.6. Strategy share (%)



List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM, 2016-2023 (\$MILLION)

TABLE 2. GLOBAL PASSIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 3. PASSIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 (\$MILLION)

TABLE 4. NORTH AMERICA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 5. EUROPE PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 6. ASIA-PACIFIC PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 7. LAMEA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 8. GLOBAL ACTIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 9. ACTIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 (\$MILLION) TABLE 10. NORTH AMERICA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 11. EUROPE ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 12. ASIA-PACIFIC ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 13. LAMEA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 14. GLOBAL ELECTRICALLY-BASED DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ANALGESICS, BY REGION, 2016-2023 (\$MILLION)

TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR HORMONE REPLACEMENT THERAPY, BY REGION, 2016-2023 (\$MILLION)

TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ISCHEMIC STROKE, BY REGION, 2016-2023 (\$MILLION)



TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR MOTION SICKNESS, BY REGION, 2016-2023 (\$MILLION)

TABLE 20. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR SMOKING CESSATION, BY REGION, 2016-2023 (\$MILLION)

TABLE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR OTHERS, BY REGION, 2016-2023 (\$MILLION)

TABLE 22. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 23. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 24. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 25. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 27. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 28. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 29. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 (\$MILLION)

TABLE 30. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 31. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 32. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 (\$MILLION)

TABLE 33. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 (\$MILLION)

TABLE 34. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 (\$MILLION)

TABLE 36. ACRUX: COMPANY SNAPSHOT

TABLE 37. ACRUX: OPERATING SEGMENTS

TABLE 38. BAYER: COMPANY SNAPSHOT

TABLE 39. BAYER: OPERATING SEGMENTS

TABLE 40. BOEHRINGER: COMPANY SNAPSHOT

TABLE 41. BOEHRINGER: OPERATING SEGMENTS

TABLE 42. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT



TABLE 43. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS

TABLE 44. ECHO: COMPANY SNAPSHOT

TABLE 45. ECHO: OPERATING SEGMENTS

TABLE 46. ENDO: COMPANY SNAPSHOT

TABLE 47. ENDO: OPERATING SEGMENTS

TABLE 48. GSK: COMPANY SNAPSHOT

TABLE 49. GSK: OPERATING SEGMENTS

TABLE 50. J&J: COMPANY SNAPSHOT

TABLE 51. J&J: OPERATING SEGMENTS

TABLE 52. MYLAN: COMPANY SNAPSHOT

TABLE 53. MYLAN: OPERATING SEGMENTS

TABLE 54. NOVARTIS: COMPANY SNAPSHOT

TABLE 55. NOVARTIS: OPERATING SEGMENTS



List Of Figures

LIST OF FIGURES

FIGURE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, 2016-2023

FIGURE 2. SEGMENTATION OF GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET

FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET

FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2016)

FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)

FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 7. TOP COMPANIES AND THEIR STRATEGIES

FIGURE 8. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES

FIGURE 9. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES

FIGURE 10. MARKET SHARE ANALYSIS, 2016

FIGURE 11. IMPACT ANALYSIS, TRANSDERMAL DRUG DELIVERY SYSTEM MARKET

FIGURE 12. GLOBAL MATRIX DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 13. GLOBAL RESERVOIR DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 (\$MILLION)

FIGURE 14. GLOBAL STRUCTURE-BASED DRUG DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 15. GLOBAL IONTOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 16. GLOBAL ELECTROPORATION DRUG DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 17. GLOBAL SONOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 18. GLOBAL OTHER DRUG DELIVERY SYSTEM MARKET, 2016-2023 (\$MILLION)

FIGURE 19. ACRUX: FINANCIALS

FIGURE 20. BAYER: FINANCIALS

FIGURE 21. BOEHRINGER: FINANCIALS

FIGURE 22. BRISTOL-MYERS SQUIBB: FINANCIALS

FIGURE 23. ECHO: FINANCIALS



FIGURE 24. ENDO: FINANCIALS FIGURE 25. GSK: FINANCIALS

FIGURE 26. J&J: FINANCIALS

FIGURE 27. MYLAN: FINANCIALS

FIGURE 28. NOVARTIS: FINANCIALS



I would like to order

Product name: Transdermal Drug Delivery Systems Market by Type of Delivery System [Passive (Matrix

System and Reservoir System), Active [Structure Based, Electrical Based, (Iontophoresis, Electroporation, and Sonophoresis), and Others] and Application (Analgesics, Hormone Replacement Therapy, Cardiovascular Disorders, Motion Sickness, and Smoking Cessation) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Product link: https://marketpublishers.com/r/T5E5EA394B6EN.html

Price: US\$ 5,540.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/T5E5EA394B6EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$